chemistry

Molecular Partners

Molecular Partners is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Molecular Partners rather than just read about it. In short: Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases.

Key takeaways

Molecular Partners belongs to chemistry; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Molecular Partners to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Molecular Partners from memory before moving on to harder problems.

Reference excerpt

Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development.

History Researchers at the University of Zürich, Switzerland formed Molecular Partners AG in 2004 while studying monoclonal antibodies. These scientists discovered and developed the DARPin technology and launched the company using this platform. Molecular Partners became a publicly traded company in November 2014, when it was listed on the SIX Swiss Exchange (ticker MOLN). Since July 2021, the company is also listed on the Nasdaq in the US under the ticker symbol MOLN.

DARPins DARPins are genetically engineered antibody mimetic proteins typically exhibiting highly specific and high-affinity target protein binding. They are derived from natural ankyrin repeat proteins. Repeat proteins are among the most common classes of binding proteins in nature, responsible for diverse functions such as cell signaling and receptor binding. DARPins constitute a new class of potent, specific and versatile small-protein therapies, and are used as investigational tools in various therapeutic and diagnostic applications. The simplest format of a DARPin is the mono-DARPin, consisting of one DARPin domain with specificity for one target. The molecular mass of a mono-DARPin is about 15 to 20 kDa (kilodaltons), depending on the exact design. Several mono-DARPins can be linked (genetically or chemically) to multi-DARPins, which then combine multiple activities in one therapy. This approach enables the design of medicines that can inhibit multiple disease-specific targets and may improve outcomes for patients living with cancer, ophthalmic diseases and other disorders. Currently, Molecular Partners has two DARPin molecules in clinical development and a broad pipeline of molecules in preclinical development.

Areas of Focus Molecular Partners is currently focusing its DARPin platform on the fields of oncology, immuno-oncology, ophthalmology, and infectious diseases.

Partnerships/Business Development Molecular Partners has negotiated three agreements with Allergan to develop therapies for ophthalmology (including abicipar), one in 2011 and two in 2012. In 2011, the company licensed its lead asset back then, abicipar, to Allergan. In 2012, Molecular Partners and Allergan expanded their relationship by signing two separate new agreements to discover, develop, and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases. Since the company's inception in 2004, Molecular Partners licensed additional DARPin candidates to other leading international pharmaceutical companies, such as Amgen, Roche or Janssen. In October 2020, as part of a joint venture to develop therapeutic drugs to combat COVID-19, the Swiss pharmaceutical giant Novartis bought 6% of all shares outstanding in Molecular Partners at 23CHF a share.

References

External links Molecular Partners official website

Worked examples

Example 1 — a first encounter with Molecular Partners

Start with the simplest possible case. Write down what Molecular Partners claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Molecular Partners before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Molecular Partners ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Molecular Partners

In research: Molecular Partners appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Molecular Partners in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Molecular Partners is common in secondary-school and first-year university syllabi. It links to neighbouring topics 2021 initial public offerings, Biotechnology companies established in 2004, Biotechnology companies of Switzerland, so understanding it makes those chapters shorter.
In everyday life: Look for Molecular Partners outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Molecular Partners” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Molecular Partners in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Molecular Partners means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Molecular Partners out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Molecular Partners in simple terms?

Why does Molecular Partners matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Molecular Partners?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Molecular Partners.